

**Form 604**  
Corporations Act 2001  
Section 671B

**Notice of change of interests of substantial holder**

To Company Name/Scheme Alterity Therapeutics Limited (**Alterity**)

ACN/ARSN 080 699 065

**1. Details of substantial holder (1)**

Name Life Biosciences LLC and each of its controlled entities listed in the Schedule (**Controlled Entities**)

ACN/ARSN (if applicable) Not applicable

There was a change in the interests of the substantial holder on

27/07/2022

The previous notice was given to the company

20/07/2022

The previous notice was dated

20/07/2022

**2. Previous and present voting power**

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in when last required, and when now required, to give a substantial holding notice to the company or scheme, are as follows:

Class of securities (4)	Previous notice		Present notice	
	Person's votes	Voting power (5)	Person's votes	Voting power (5)
Ordinary Shares	213,238,233	8.9%	179,287,533	7.4%

**3. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest of the substantial holder or an associate in voting securities of the scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (6)	Consideration given in relation to change (7)	Class and number of securities affected	Person's votes affected
As set out in Annexure A	Life Biosciences LLC and its Controlled Entities Listed in the Schedule	Decrease in relevant interest through open market sales	As set out in Annexure A	As set out in Annexure A	As set out in Annexure A

**4. Present relevant interests**

Particulars of each relevant interest of the substantial holder in voting securities after the change are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Nature of relevant interest (6)	Class and number of securities	Person's votes
Life Biosciences LLC and its Controlled Entities Listed in the Schedule	Life Biosciences LLC	Life Biosciences LLC	Registered holder of Alterity Ordinary Shares	179,287,533 Ordinary Shares represented by 2,988,125 American Depositary Shares	7.4%

## 5. Changes in association

The persons who have become associates (2) of, ceased to be associates of, or have changed the nature of their association (9) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
N/A	N/A

## 6. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Alterity Therapeutics Limited	Level 3, 460 Bourke Street, Melbourne Vic, 3000
Life Biosciences LLC	75 Park Plaza, 3 <sup>rd</sup> Floor, Boston MA 02116 USA
Controlled Entities of Life Biosciences LLC	See the Schedule

## Signature

print name Ivan Kaplan

capacity Authorized Signatory

sign here

  
Ivan Kaplan (Aug 1, 2022 22:17 EDT)

date August 1, 2022

## DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 6 of the form.
- (2) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (4) The voting shares of a company constitute one class unless divided into separate classes.
- (5) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.
- (6) Include details of:
  - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (7) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included on any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".
- (9) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

## Schedule

The following entities are associates of Life Biosciences LLC as they are controlled by Life Biosciences LLC:

Name of Controlled Entity	Address of Controlled Entity
Continuum Biosciences, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Iduna Therapeutics, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Jumpstart Fertility, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Life Biosciences Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Life Lua Technologies, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116
Selphagy Therapeutics, Inc.	75 Park Plaza, Third Floor, Boston, MA 02116

This is the Schedule of 1 page referred to in the Form 604, Notice of change of interests of substantial holder signed by me and dated August 1, 2022.

  
Ivan Kaplan (Aug 1, 2022 22:17 EDT)

Ivan Kaplan  
Authorized Signatory  
Life Biosciences LLC

## Annexure A

This is Annexure A of 1 page referred to in *Form 604: Notice of change of interests of substantial holder*.

Trade Date	Settlement Date	Shares Sold*	Share Price	Consideration
19/7/2022	21/7/2022	39,092	\$0.6207	\$24,264.40
20/7/2022	22/7/2022	25,226	\$0.6062	\$15,292.00
21/7/2022	25/7/2022	10,710	\$0.6007	\$6,433.50
22/7/2022	26/7/2022	22,566	\$0.6232	\$14,063.13
25/7/2022	27/7/2022	11,845	\$0.6042	\$7,156.75
26/7/2022	28/7/2022	150,799	\$0.6029	\$90,916.72
27/7/2022	29/7/2022	106,102	\$0.6051	\$64,202.32
28/7/2022	01/8/2022	72,190	\$0.6093	\$43,985.37
29/7/2022	02/8/2022	98,620	\$0.6083	\$59,990.55
01/8/2022	03/8/2022	28,695	\$0.6000	\$17,217.00

\*Denominated in American Depositary Shares